Corcept Therapeutics reported a significant increase in net income to $126.8 million for the third quarter of 2026, compared to $19.7 million in the prior year, driven by a 64% increase in product revenue. The company maintained a strong balance sheet with over $1 billion in total assets and continued its stock repurchase program, though it recorded a net loss in the first quarter of the year.
Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, a 64% increase year-over-year, driven by strong growth in Korlym and the rapid uptake of Lifyorli in ovarian cancer. Net income rose significantly to $126.8 million, or $1.01 per diluted share, while the company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.
Term
Q3 2026
“Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the growth of our endocrinology business. Lifyorli’s uptake in ovarian cancer has been both very rapid and broad. Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it. We expect continued growth in both businesses and have reiterated our 2026 revenue guidance of $1.1 – $1.2 billion.”
Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer
“The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome. Optimal care starts with screening and a correct diagnosis. The ADA/EASD report also identifies mifepristone as a potential treatment, citing the positive results of our CATALYST trial.”
Bill Guyer, PharmD, Corcept’s Chief Development Officer